| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Outline of Final Research Achievements |
Sarcopenia was diagnosed according to the AWGS criteria based on skeletal muscle mass index (SMI) measured by bioelectrical impedance analysis, muscle strength, and gait speed. Cognitive function, depression, and activities of daily living was evaluated using the MMSE, GDS-15, and Barthel Index(BI). In addition, we assessed blood biomarkers of nutritional status.
Sarcopenic group showed lower height, weight, cognitive function and BI score. In blood biomarkers, it showed lower isoleucine, leucine, total amino acids, EAAs and BCAAs and higher adiponectin, total cholesterol and high-density lipoproteins.
Ten patients with sarcopenia underwent a 6-month intervention of 2400mg of leucine supplementation. As for the nutritional status, there were no significant differences between pre-/postintervention. There were none the worse for status despite high risk group. Therefore, leucine supplementation may be the nutritional approach to the prevention and treatment of sarcopenia.
|
